SAN DIEGO & ARLINGTON, Va.--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, will be presenting today at The Center for Business Intelligence’s (CBI) 3rd Annual Obesity Drug Development Summit. Ronald Landbloom, M.D., Vice President of Medical and Regulatory Affairs at Orexigen, will discuss a summary of clinical trial results to date on Contrave™, the Company’s lead obesity drug candidate.
